Jim Cramer Considers nCino As Winner, Prefers This Stock Over Perficient
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Chewy, Inc (NYSE: CHWY) and recommended buying the stock.
Morgan Stanley Maintains Equal-Weight on Jazz Pharmaceuticals, Lowers Price Target to $174
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Equal-Weight and lowers the price target from $176 to $174.
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
Citigroup Initiates Coverage On Jazz Pharmaceuticals with Buy Rating, Announces Price Target of $200
Citigroup analyst Navann Ty initiates coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy rating and announces Price Target of $200.
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 4)
SEC Charges Former Goldman Sachs Officer For Insider Trading On 2 M&A Deals
The Securities and Exchange Commission has charged a former Goldman Sachs (NYSE:GS) compliance analyst with using confidential information to generate over $471,000…
Needham Initiates Coverage With Buy For This Narcolepsy Player
Needham has initiated Avadel Pharmaceuticals Plc (NASDAQ:AVDL) coverage with a Buy rating and $17 price target. Analyst Ami Fadia sees an…
Needham Initiates Coverage On Jazz Pharmaceuticals with Buy Rating, Announces Price Target of $220
Needham analyst Ami Fadia initiates coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy rating and announces Price Target of $220.